
TARA Stock Forecast & Price Target
TARA Analyst Ratings
Bulls say
Protara Therapeutics Inc is well-positioned for growth due to its promising interim data from the Phase 2 ADVANCED-2 trial, showcasing TARA-002's efficacy and durability in BCG-naïve patients, which is essential for competing in this market. The potential first-mover advantage in the BCG-naïve setting, combined with proactive FDA engagement for a registrational path, suggests a credible opportunity for Protara to capture significant market share in the near future. Additionally, strong responses and safety profiles observed in both lymphatic malformations and intestinal failure associated liver disease highlight the company's capacity for delivering transformative therapies, reinforcing a favorable outlook for its ongoing developments.
Bears say
Protara Therapeutics has been facing significant challenges related to its ongoing development programs, particularly TARA-002 and IV choline chloride, which could impact timely commercialization and overall revenue generation. The company's financial metrics indicate increasing operational costs without a corresponding rise in revenue, leading to concerns about sustainable cash flow and funding capabilities for its pipeline initiatives. Additionally, potential regulatory hurdles and market competition for its targeted therapies further contribute to a negative outlook regarding the stock's future performance.
This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TARA Analyst Forecast & Price Prediction
Start investing in TARA
Order type
Buy in
Order amount
Est. shares
0 shares